Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine)

References

• Thanou M, Duncan R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr. Opin. Invest. Drugs. 2003;4:701–709.
   PubMedGoogle Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010;62:90–99.10.1016/j.phrs.2010.03.005
   PubMed Web of Science ®Google Scholar
• Fossa SD, Vaage S, Letocha H, Iversen J, Risberg T, Johannessen DC, Paus E, Smedsrud T. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered. Scand. J. Urol. Nephrol. 2002;36:34–39.
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Ferrandina G, Ludovisi M, Testa A, Lorusso D, Gbaguidi N, Breda E, Mancuso S, Scambia G. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br. J. Cancer. 2003;89:1180–1184.10.1038/sj.bjc.6601284
   PubMed Web of Science ®Google Scholar
• Chau Y, Padera RF, Dang NM, Langer R. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int. J. Cancer. 2006;118:1519–1526.10.1002/ijc.21495
   PubMed Web of Science ®Google Scholar
• Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Cancer Sci. 2002;93:1145–1153.10.1111/cas.2002.93.issue-10
   Google Scholar
• Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010;11:129–141.10.2174/138920010791110827
   PubMed Web of Science ®Google Scholar
• Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chem. 2005;16:122–130.10.1021/bc0498166
   PubMed Web of Science ®Google Scholar
• Gillies ER, Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today. 2005;10:35–43.10.1016/S1359-6446(04)03276-3
   PubMed Web of Science ®Google Scholar
• Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat. Biotechnol. 2005;23:1517–1526.10.1038/nbt1171
   PubMed Web of Science ®Google Scholar
• D’Emanuele A, Attwood D. Dendrimer–drug interactions. Adv. Drug Delivery Rev. 2005;57:2147–2162.10.1016/j.addr.2005.09.012
   PubMed Web of Science ®Google Scholar
• Boas U, Heegaard PM. Dendrimers in drug research. Chem. Soc. Rev. 2004;33:43–63.10.1039/b309043b
   PubMed Web of Science ®Google Scholar
• Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chem. 2000;11:910–917.10.1021/bc0000583
   PubMed Web of Science ®Google Scholar
• Han L, Huang R, Liu S, Huang S, Jiang C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol. Pharm. 2010;7:2156–2165.10.1021/mp100185f
   PubMed Web of Science ®Google Scholar
• Kono K, Fukui T, Takagishi T, Sakurai S, Kojima C. Preparation of poly(ethylene glycol)-modified poly(amidoamine) dendrimers with a shell of hydrophobic amino acid residues and their function as a nanocontainer. Polymer. 2008;49:2832–2838.10.1016/j.polymer.2008.04.048
   Web of Science ®Google Scholar
• Kono K, Kojima C, Hayashi N, Nishisaka E, Kiura K, Watarai S, Harada A. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials. 2008;29:1664–1675.10.1016/j.biomaterials.2007.12.017
   PubMed Web of Science ®Google Scholar
• Kojima C, Suehiro T, Watanabe K, Ogawa M, Fukuhara A, Nishisaka E, Harada A, Kono K, Inui T, Magata Y. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater. 2013;9:5673–5680.10.1016/j.actbio.2012.11.013
   PubMed Web of Science ®Google Scholar
• Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Frechet JMJ, Dy EE, Szoka FC. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Nat. Acad. Sci. USA. 2006;103:16649–16654.10.1073/pnas.0607705103
   PubMed Web of Science ®Google Scholar
• Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of pegylation degree and drug conjugation style. Biomaterials. 2010;31:1360–1371.10.1016/j.biomaterials.2009.10.044
   PubMed Web of Science ®Google Scholar
• Ohsaki M, Okuda T, Wada A, Hirayama T, Niidome T, Aoyagi H. In vitro gene transfection using dendritic poly(L-lysine). Bioconjugate Chem. 2002;13:510–517.10.1021/bc015525a
   PubMed Web of Science ®Google Scholar
• Okuda T, Kawakami S, Maeie T, Niidome T, Yamashita F, Hashida M. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J. Controlled Release. 2006;114:69–77.10.1016/j.jconrel.2006.05.009
   PubMed Web of Science ®Google Scholar
• Okuda T, Kawakami S, Akimoto N, Niidome T, Yamashita F, Hashida M. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J. Controlled Release. 2006;116:330–336.10.1016/j.jconrel.2006.09.012
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Owen DJ, Boyd BJ, Porter CJH. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J. Controlled Release. 2011;152:241–248.10.1016/j.jconrel.2011.02.005
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M, Owen DJ, Porter CJH. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomed.: Nanotech. Biol. Med. 2012;8:103–111.10.1016/j.nano.2011.05.013
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Kelly BD, Cullinane C, Sberna G. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol. Pharm. 2012;9:422–432.10.1021/mp200522d
   PubMed Web of Science ®Google Scholar
• Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA, Bianco A, Vargesson N, Kanthou C, Florence AT, Tozer GM, Kostarelos K. Systemic antiangiogenic activity of cationic poly-L-LYSINE dendrimer delays tumor growth. Proc. Nat. Acad. Sci. 2010;107:3966–3971.10.1073/pnas.0908401107
   PubMed Web of Science ®Google Scholar
• Al-Jamal KT, Al-Jamal WT, Wang JTW, Rubio N, Buddle J, Gathercole D, Zloh M, Kostarelos K. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. ACS Nano. 2013;7:1905–1917.10.1021/nn305860k
   PubMed Web of Science ®Google Scholar
• Stryer L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. J. Mol. Biol. 1965;13:482–495.10.1016/S0022-2836(65)80111-5
   PubMedGoogle Scholar
• Liu Y, Tseng YC, Huang L. Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm. Res. 2012;29:3273–3277.10.1007/s11095-012-0818-1
   PubMed Web of Science ®Google Scholar
• Arora HC, Jensen MP, Yuan Y, Wu A, Vogt S, Paunesku T, Woloschak GE. Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res. 2012;72:769–778.10.1158/0008-5472.CAN-11-2890
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004;56:185–229.10.1124/pr.56.2.6
   PubMed Web of Science ®Google Scholar
• Patil RR, Guhagarkar SA, Devarajan PV. Engineered nanocarriers of doxorubicin: a current update. Crit. Rev. Ther. Drug Carrier Syst. 2008;25:1–61.10.1615/CritRevTherDrugCarrierSyst.v25.i1
   PubMed Web of Science ®Google Scholar